LBA18 Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results
Ning Lin(Dana-Farber Cancer Institute), Eva Ciruelos(Hospital Universitario 12 De Octubre), G. Jerusalem(University of Liège), V. Mueller(Universität Hamburg), Naoki Niikura(Tokai University), G. Viale(European Institute of Oncology), R. Bartsch(Medical University of Vienna), C. Kurzeder(Breast Center), R. C. Connolly(Cork University Hospital), Sally Baron‐Hay(Royal North Shore Hospital), M. Gion Cortes(Villa Maria Hospital), V. Guarneri(University of Padua), Giampaolo Bianchini(IRCCS Ospedale San Raffaele), H. Wildiers(KU Leuven), Santiago Escrivá-de-Romaní(Vall d'Hebron Hospital Universitari), Manoj Prahladan(AstraZeneca (United Kingdom)), Helen Bridge(AstraZeneca (United Kingdom)), Sumedha Verma(AstraZeneca (United States)), Nadia Harbeck(LMU Klinikum)
Cited by 3Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis